Back to top

Analyst Blog

Elan Corporation plc recently closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec (BIIB - Analyst Report). As a result, Biogen gained full strategic, commercial and operational control over the multiple sclerosis drug.

The transaction was initially announced in Feb 2013. As per the terms of the transaction Biogen made an upfront payment of $3.25 billion to Elan. Elan stated that it will invest a portion of the amount in different business assets. The company intends to refinance its outstanding debt through a share repurchase program by utilizing $1 billion of the upfront proceeds.

Elan is also eligible to receive a royalty payment of 12% on worldwide net sales of Tysabri (for all indications) for the first year. After the first year, Elan will receive a royalty of 18% on up to $2 billion of global net sales of Tysabri and 25% thereafter. Tysabri sales came in at $1.6 billion in 2012.

We note that last month encouraging data was announced on Tysabri. Data showed that Tysabri treatment resulted in lower rate of first relapse compared to other multiple sclerosis drugs.

We believe that the loss of Tysabri is huge setback at to Elan, since the product was its primary source of revenue. We expect Elan to actively pursue in-licensing deals or acquisitions to boost its product portfolio.

Elan, a biotechnology company, currently carries a Zacks Rank #5 (Strong Sell). Currently, well-placed biotech stocks include Cytokinetics Inc. (CYTK - Snapshot Report) and QLT Inc. (QLTI - Analyst Report). Both the stocks carry a Zacks Rank #1 (Strong Buy). Biogen also carries a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
THE PANTRY… PTRY 21.24 +3.16%
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.14 +2.55%
WILLDAN GRO… WLDN 11.77 +2.13%
CLAYTON WIL… CWEI 117.50 +1.95%